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Objectives: The aim of this study is to investigate the
pattern of lymphatic metastasis and suggest a lymph node
dissection (LND) strategy for thymic malignancies.
Methods: We retrospectively reviewed 131 thymic malig-
nancy patients who had undergone LND. The recently
introduced nodal map of the International Thymic Malig-
nancy Interest Group/International Association for the
Study of Lung Cancer and the TNM (tumor, node, metas-
tasis) stage classiﬁcation were used for grouping and stag-
ing the lymph nodes. The pattern of lymphatic metastasis
and factors in lymphatic metastasis were investigated.
Results: Node metastasis was detected in 13 patients (N1
in six and N2 in seven). Six N2 patients (86%) had right
paratracheal node (RPN) metastases. The rates of node
metastasis were 1% at T1 and 37.5% at T2/3 (p <
0.001). The rates of node metastasis were 8% in the M0
and 43% in the M1 (p ¼ 0.03). The rate was higher for
thymic carcinoma (25%) than for thymoma (5.1%, p ¼
0.01), and the rates also differed between the subtypes of
thymoma. There was no node metastasis of the A, AB, or
B1 types. Tumor size was also a signiﬁcant factor in node
metastasis. The optimal cutoff value for the node
metastasis was 6 cm and the speciﬁcity was 62%. Only
16% of the patients had received a preoperative histo-
logic diagnosis. All patients with node metastasis had
TNM stage II or higher thymic malignancy. The freedom
from recurrence rate of the pN1/2 was signiﬁcantly
worse than that of the pN0 (5-year rate 38.5% versus
87.9%, p < 0.001).
Conclusion: A status of stage II or higher was the most
speciﬁc predictor of node metastasis, and the RPN was a
crucial station for lymphatic metastasis in thymic malig-
nancies. Thus, LND including RPN is recommended in stage
II or higher thymic malignancies.Journal of Thoracic Oncology Vol. 11 No. 1: 108-114 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Lymph node metastasis is one of the important
prognostic factors of thymic malignancies, and its inci-
dence is not low.1 Little is known about the pattern of
lymph node metastasis and the effect of lymph node
dissection (LND) on thymic malignancies, however,
because there has been no mapping of common lymph
nodes or consensus about LND for thymic malignancies.
Although LND is an important part of oncologic surgery
and is recommended for other thoracic malignancies, it
is not a standard procedure in thymic malignancy sur-
gery.2,3 LND can help identify pathologic stage more
accurately and improve locoregional disease control. In
2011, the International Thymic Malignancy Interest
Group (ITMIG) submitted a recommendation for LND in
thymic malignancies.4 The ITMIG recommendation was
developed on the basis of a single report and required
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been suggested for thymic carcinoma, particularly for
tumors invading adjacent structures.5 In a previous
report, we applied the lymph node classiﬁcation system
of Yamakawa et al., which is not a lymph node map but a
nodal stage classiﬁcation system, and the Masaoka-Koga
stage classiﬁcation system, which is not a tumor, node,
metastasis (TNM) staging system but a conﬂuent staging
system.6,7 In the meantime, the ITMIG and the Interna-
tional Association for Study of Lung Cancer (IASLC)
proposed a new lymph node map and a forthcoming
(eighth) edition of the TNM stage classiﬁcation system
for thymic malignancies.8–11 Thus, it is necessary to
verify and modify the ITMIG recommendation for LND
according to the ITMIG/IASLC lymph node map and
IASLC/ITMIG TNM stage classiﬁcation system. This
study analyzed the pattern of lymph node metastasis on
the basis of the ITMIG/IASLC lymph node map and the
IASLC/ITMIG TNM stage classiﬁcation system with the
aim to modify the ITMIG recommendation for LND in
thymic malignancies in line with new proposals.
Patients and methods
A total of 201 patients who had undergone thymec-
tomy for thymic malignancy with or without LND be-
tween January 1996 and February 2011 were reviewed
retrospectively. All the patients had pathologically
proven thymic malignancies, including thymoma, thymic
carcinoma, and thymic neuroendocrine tumor. Thymic
neuroendocrine carcinomas were grouped with thymic
carcinomas. Patients with macroscopic incomplete re-
sections (R2) were excluded. All patients were evaluated
through a review of their history, clinical examination,
chest radiograph, and chest computed tomography
before the surgery. The demographic characteristics,
pathologic ﬁndings, TNM stage, number of dissected
lymph nodes, station of the lymph nodes, results of
pathologic analysis of the lymph nodes, and follow-up
data on recurrence and survival rates were obtained
through reviews of patients’ medical records and tele-
phone interviews. The histologic subtypes that had been
classiﬁed on the basis of the Müller-Hermelink classiﬁ-
cation before 2001 were converted to the corresponding
World Health Organization (WHO) histologic classiﬁca-
tion of tumors of the thymus.12 We adopted the ITMIG/
IASLC lymph node map and the IASLC/ITMIG TNM stage
classiﬁcation system for thymic malignancies.8,10,11 The
lymph node stations and stages were determined by
reviewing patients’ surgical records and pathologic re-
ports. The duration of survival or time to recurrence
were calculated from the date of the operation to the
date of the adverse event or the last follow-up. The
follow-up surveillance period ran until January 2014.
Lymph node dissection status was investigated for allpatients. In patients with lymph node dissection, the
patterns of the lymph node metastases were investigated
from the standpoint of clinicopathologic factors such as
the T stage, tumor size (longest diameter), M stage, and
histologic subtype. The continuous variables were
compared using a t test or analysis of variance. The re-
lationships between two continuous variables were
estimated with a linear regression analysis. The discrete
variables were compared with a chi-square test or
Fisher’s exact test. A receiver operating characteristic
curve was used to determine the optimal cutoff value of
tumor size for prediction of node metastasis. Freedom
from recurrence (FFR) was the primary parameter for
long-term prognosis. The overall survival rate and FFR
rate were calculated by the Kaplan-Meier method, and a
comparison of the subgroups was conducted by using a
log-rank test. All p values less than 0.05 were considered
statistically signiﬁcant. The statistical analyses were
performed with IBM SPSS statistics 21 (IBM, Armonk,
NY). This study was approved by the Institutional Re-
view Board of Seoul National University Hospital, and it
complied with the Declaration of Helsinki.
Lymph node dissection
As described in a previous report, the standard pro-
cedure at the time of the study was a total thymectomy
through median sternotomy. An en bloc resection of the
adjacent structure(s) was performed in all cases with
signs suggestive of invasion. The perithymic lymph
nodes were dissected en bloc with the tumor and the
thymus. Other lymph nodes were dissected separately.
One author (Y.T.K.) performed LND for thymic malig-
nancies and pursued this strategy throughout the study
period. The extent of lymph node dissection was decided
on the basis of tumor extent. Over the study period, each
lymph node was classiﬁed according to the nomencla-
ture of the lung cancer lymph node map.13 The lymph
node stations were reclassiﬁed according to the new
ITMG/IASLC lymph node map.8 The anterior region (N1)
included the lower anterior cervical, perithymic, pre-
vascular, para-aortic, ascending aortic, superior phrenic,
supradiaphragmatic, inferior phrenic, and pericardial
node groups. The deep region (N2) included the deep
cervical, supraclavicular, upper and lower paratracheal,
subaortic, subcarinal, hilar, and internal mammary node
groups. All nodes outside the anterior and deep regions
were regarded as M components.
Results
Baseline characteristics
The clinical and pathologic features of the 201 pa-
tients are summarized in Table 1. Histologically, 80.6%
of the patients (n ¼ 162) had thymoma, whereas 19.4%
Table 1. Patient characteristics and comparison of the
groups with and without lymph node dissection
Characteristic
Total
(N ¼ 201)
Lymph node
dissection
(N ¼ 131)
No Lymph
node
dissection
(N ¼ 70) p
Age 53 ± 13 55 ± 13 50 ± 13 0.015
Sex 0.30
Male 102 70 (69%) 32 (31%)
Female 99 61 (62%) 38 (38%)
Myasthenia gravis 0.44
Yes 40 24 (60%) 16 (40%)
No 161 107 (67%) 54 (33%)
Size (cm) 5.9 ± 2.9 6.0 ± 3.1 5.9 ± 2.8 0.84
T stage 0.002
T1 164 99 (60%) 65 (40%)
T2/3 37 32 (87%) 5 (13%)
M stage 0.74
M0 191 124 (65%) 67 (35%)
M1a/b 10 7 (70%) 3 (30%)
Histologic subtype 0.014
Thymic carcinoma 39 32 (82%) 7
Thymoma 162 99 (61%) 63 (39%) 0.23
A 12 7 (58%) 5 (42%)
AB 44 29 (66%) 15 (34%)
B1 40 23 (58%) 17 (42%)
B2 38 21 (55%) 17 (45%)
B3 28 19 (68%) 9 (32%)
Items in italics show subgroup analysis of thymoma.
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were at the pathologic stage T1, two were at stage T2,
and 35 were at stage T3. There were no T4 patients
eligible for inclusion in the analysis. The numbers of
patients by pathologic N stage were as follows: NX, 70
patients; N0, 118 patients; N1, six patients; and N2, seven
patients. The numbers of patients in the various M stages
were as follows: M0, 191 patients; M1a, seven patients;
and M1b, three patients. The mean tumor size was 5.9 ±
2.9 cm (range 1.3 to 19 cm). LND was performed in 131
patients (65.2%). A preoperative biopsy was performed
for 21 patients (16%). The mean age of the LND group
was signiﬁcantly higher than that of the no-LND group.
Tumor size did not differ between the two groups. LND
was performed more frequently in patients with a tumor
status of T2 or higher and with thymic carcinoma. The
patients with thymic carcinoma were signiﬁcantly older
than the patients with thymoma (59 ± 12 years versus
52 ± 13 years, p ¼ 0.001). There was no difference in
LND rate between the subtypes of thymoma.Outcomes of lymph node dissection
A total of 1348 lymph nodes in 131 patients were
dissected. The mean number of dissected lymph nodes
per patient was 10.3 ± 8.5 (range 1 to 48). In 59 patients(45%), 10 or more lymph nodes were dissected. The
number of dissected lymph nodes did not differ signiﬁ-
cantly according to sex, T stage, or M stage. Moreover,
the number of dissected lymph nodes had no correlation
with age (r ¼ 0.11, p ¼ 0.07) or size of the tumor (r ¼
0.09, p ¼ 0.33). The number of dissected lymph nodes
was larger in patients with thymic carcinoma, however.
A total of 582 anterior regional lymph nodes (N1) in 107
patients (81.7%) were dissected, with a mean number of
5.4 ± 4.1 (range 1 to 18). Of these 582 anterior regional
nodes, 517 (88.8%) were perithymic, prevascular, or
lower anterior cervical nodes. A total of 65 para-aortic
lymph nodes in 24 patients were dissected. A total of
766 deep regional nodes (N2) in 83 patients (63.4%)
were dissected, with a mean number of 9.2 ± 7.8 (range
1 to 36). A total of 486 right paratracheal lymph nodes in
62 patients (47.3%) were dissected. Lymph node
metastasis was conﬁrmed in 13 patients. The preoper-
ative radiologic studies revealed nine patients (69%)
with metastasis in suspicious nodes. Six patients were at
the pathologic stage N1 and 7 were at the N2 stage. Two
N2 patients showed metastasis in both N1 and N2 nodes.
Six pN2 patients (86%) showed metastasis in the right
paratracheal node groups. Subcarinal lymph node
metastasis was detected in a patient with B2 thymoma
with lung invasion (Table 2). The rates of node metas-
tasis for each T stage were 1% at T1 (one of 99), 50% at
T2 (one of two), and 63.3% at T3 (19 of 30). The rate of
node metastasis was signiﬁcantly higher in patients with
T2 or higher stage. (T1, 1%; T2/3, 37.5%; p < 0.001).
The only patient at stage T1 with node metastasis also
had pleural seeding (M1a). The rates of node metastasis
for the M stages were 8.1% for M0 and 42.9% for M1.
The patients at stage M1 showed a signiﬁcantly higher
rate of node metastasis (p ¼ 0.03). The node metastasis
rates according to WHO histologic type were 14.3% for
B2, 10.5% for B3, and 25% for the thymic carcinoma
group. There was no lymph node metastasis in 59 pa-
tients with A, AB, or B1 thymoma. The rate of node
metastasis of thymic carcinoma was signiﬁcantly higher
than that of thymoma (25% versus 5.1%, p ¼ 0.001).
However, there was no signiﬁcant difference in the node
metastasis rate between B2, B3, and thymic carcinoma
(p ¼ 0.2). The node metastasis rates at the same T stage
did not differ between thymoma and thymic carcinoma.
In the T1 group, the rates of node metastasis were 1.2%
for thymoma and 0% for thymic carcinoma (p ¼ 0.7). In
the T2/3 group, the node metastasis rates were 30.8%
for thymoma and 42.1% for thymic carcinoma (p ¼ 0.5).
The tumor size was signiﬁcantly larger in the node
metastasis group than in the node-negative group
(Table 3). In the receiver operating characteristic curve
analysis of tumor size, the area under the curve was 0.78
(95% conﬁdence interval: 0.65 to 0.91, p ¼ 0.001) and
Table 2. Patients with lymph node metastasis
Size
(cm) Type T N M Suspicious nodes Metastatic nodes Recurrence site
DFI
(m)
1 11 B2 3 1 1a Prevascular Prevascular No 61
2 8 B3 1 1 1a No Perithymic Pleura 31
3 6 C 3 1 0 Unknown Perithymic No 174
4 6 C 3 1 0 RPN Perithymic Para-aortic node, RPN 30
5 6.5 C 3 1 0 Prevascular Prevascular Right jugular nodes 12
6 10 C 3 1 0 Perithymic Perithymic Liver 6
7 9 B2 3 2 0 No RPN No 160
8 9.9 B2 3 2 0 Right internal mammary Right internal mammary, right hilar No 37
9 19 B3 2 2 0 Perithymic, RPN RPN Lung, paraesophageal node 22
10 3.5 C 3 2 0 RPN RPN No 51
11 5.8 C 3 2 1a No Perithymic, RPN Lung 23
12 8.5 C 3 2 0 Perithymic Perithymic, RPN Bilateral supraclavicular nodes 9
13 13 C 3 2 0 Para-aortic, RPN, subcarinal RPN, subcarinal Liver 3
DFI, disease-free interval; RPN, right paratracheal node.
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metastasis was 6 cm (sensitivity 77%, speciﬁcity 62%).
The node metastasis rate was 5% for tumors 6 cm or
smaller and 17.6% for tumors larger than 6 cm (p ¼
0.018). There was no difference between the node-
negative and node metastasis groups in terms of sex,
age, presence of myasthenia gravis, or extent of LND.Table 3. Comparison of N0 and N1/2 patients
Characteristic
N0
(n ¼ 118)
N1/2
(n ¼13) p
Age 55 ± 13 58 ± 14 0.44
Sex 0.56
Male 64 (91.4%) 6 (8.6%)
Female 54 (88.5%) 7 (11.5%)
Myasthenia Gravis 0.30
Yes 23 (95.8%) 1 (4.2%)
No 95 (88.8%) 12 (11.2%)
Extent of node dissection 0.85
Anterior region 44 (91.7%) 4 (8.3%)
Deep region 21 (87.5%) 3 (12.5%)
Both 53 (89.8%) 6 (10.2%)
Tumor size (cm) 5.6 ± 2.4 8.9 ± 4.0 0.001
T stage 0.001
T1 98 (99%) 1 (1%)
T2/3 20 (62.5%) 12 (37.5%)
M stage 0.03
M0 114 (91.9%) 10 (8.1%)
M1 4 (57.1%) 3 (42.9%)
Histologic subtype 0.01
Thymic carcinoma 24 (75%) 8 (25%)
Thymoma 94 (94.9%) 5 (5.1%) 0.09
A 7 (100%) -
AB 29 (100%) -
B1 23 (100%) -
B2 18 (85.7%) 3 (14.3%)
B3 17 (89.5%) 2 (10.5%)
Items in italics show subgroup analysis of thymoma.Prognosis
The median duration of follow-up was 60 months and
the overall 10-year survival rate was 73.3%. An isolated
nodal recurrence was detected in three node-positive
patients with thymic carcinoma. One N1 patient had
nodal recurrences in the para-aortic and right para-
tracheal nodes. Another N1 patient had recurrences in
the right deep jugular lymph nodes. One N2 patient had a
recurrence in the bilateral supraclavicular lymph nodes.
One pT1N0M0 patient with B2 thymoma had a recur-
rence in the subcarinal node and right middle lobe. The
FFR rates for the entire cohort of patients were 82.4% at
year 5 and 76.2% at year 10. The 5-year FFR rates were
87.9% in the N0 group and 38.5% in the N1/2 group; the
difference was signiﬁcant (p < 0.001) (Fig. 1). There
were no differences between the FFR rates in the N1 and
N2 groups (5-year rates: N1 ¼ 33.3% and N2 ¼ 42.9%,
p ¼ 0.96), however. In the subgroup analyses according
to thymoma and thymic carcinoma, those in the N1/2
groups also showed signiﬁcantly worse prognoses than
did those in the N0 group. For thymoma, the 5-year FFR
rates were 92.5% in the N0 group and 60% in the N1/2
group (p ¼ 0.032). For thymic carcinoma, the 5-year FFR
rates were 67.6% in the N0 group and 25% in the N1/2
group (p ¼ 0.014).
Discussion
This study suggests that IASLC/ITMIC stage is the
most speciﬁc predictor of lymph node metastasis and the
right paratracheal lymph node group is crucial to
lymphatic metastasis in thymic malignancies. Lymph
node metastasis is an important prognostic factor and is
not uncommon in thymic malignancies; however, lymph
node metastasis in thymic malignancies has been
underestimated and has received little attention. As a
result, there has been no standard nodal mapping or
Figure 1. Kaplan-Meier curves of freedom from recurrence in
pN0 and pN1/2 patients.
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about lymph node metastasis in thymic malignancy. To
break this vicious cycle, the ITMIG proposed a recom-
mendation for LND in thymic malignancies in 2011. The
ITMIG recommended removal of any suspicious lymph
nodes, routine removal of anterior mediastinal
lymph nodes, and systematic sampling of intrathoracic
lymph nodes in thymomas with adjacent organ involve-
ment. For thymic carcinoma, the systematic removal of
anterior mediastinal, intrathoracic, supraclavicular, and
lower cervical lymph nodes was recommended.4 The
ITMIG and IASLC recently proposed a lymph node map
and TNM stage classiﬁcation system to build a founda-
tion for communication and collaboration in the study of
thymic malignancies. A nodal stage classiﬁcation for
thymic malignancies was proposed by Yamakawa and
Masaoka in 1991.6 However, this classiﬁcation was not a
lymph node map but a nodal stage classiﬁcation system,
with no description of the exact anatomical location of
each lymph node group. The ITMIG/IASLC lymph node
map is the ﬁrst systematized and practical lymph node
map for thymic malignancies. The ITMIG/IASLC lymph
node map classiﬁes the locoregional lymph nodes into
anterior regional nodes (N1) and deep regional nodes
(N2). The anterior regional nodes are the low anterior
cervical, perithymic, prevascular, para-aortic, and
supradiaphragmatic nodes. The deep regional nodes are
the lower jugular, supraclacvicular, internal mammary,
paratracheal, subaortic, subcarinal, and hilar nodes. A
distinct feature of the ITMIG/IASLC nodal map is that the
para-aortic lymph node is classiﬁed as an N1 node and
the proximal cervical lymph node groups (i.e., the low
anterior cervical, lower jugular, and supraclavicularnodes) are considered locoregional lymph nodes.8 The
IASLC/ITMIG TNM staging system is an evidence-based
stage classiﬁcation system that was developed on the
basis of a large international retrospective database
covering more than 10,000 patients.9 In the IASLC/
ITMIG TNM stage classiﬁcation system, the T stages are
classiﬁed according to level of invasion as follows: T1,
invasion of level 1 structures (thymus, anterior medi-
astinal fat, mediastinal pleura); T2, invasion of a level 2
structure (pericardium), T3, invasion of level 3 struc-
tures (lung, brachiocephalic vein, superior vena cava,
phrenic nerve, chest wall, hilar pulmonary vessels); and
T4, invasion of level 4 structures (aorta, arch vessels,
intrapericardial pulmonary artery, myocardium, trachea,
esophagus).10 The N stages are classiﬁed as N0, N1, and
N2. No N3 stage exists, and metastases in lymph nodes
other than the N1 and N2 nodes are classiﬁed as M1b.11
The deﬁnitions of the M stages are identical to those in
the Masaoka-Koga classiﬁcation.11 The stage groupings
are as follows: I, T1N0M0; II, T2N0M0; IIIa, T3N0M0;
IIIb, T4N0M0; IVa, N1 or M1a; and IVb, N2 or M1b.9
This study supports the ITMIG recommendation for
LND, which holds that patient selection on the basis of
tumor invasiveness is reasonable. In our study, all lymph
node metastases but one were detected at the T2 or T3
stages, and the node metastasis rate in T2/3 patients
was 37.5 %. The only T1 patient with lymph node
metastasis had concomitant pleural dissemination
(M1a). This ﬁnding is probative evidence that the T
classiﬁcation of the IASLC/ITMIG TNM staging system
according to the structure level is reasonable and that
the stage T1 encompasses a relatively homogenous
group in terms of disease progression. Kondo et al. also
reported that lymph node metastasis was more frequent
in thymic malignancies with invasion of neighboring
organs than in those without invasion.1 They reported
that the lymph node metastasis rates were 0.003% at T1
and 5.6% at T2 or higher for thymoma and 14.8% at T1
and 28.8% at T2 or higher for thymic carcinoma.1 The
M1 patients in this study also showed a signiﬁcantly
higher rate of lymph node metastasis than the M0 pa-
tients. These ﬁndings suggest that lymph node metas-
tasis occurs only in stage II or higher thymic
malignancies. Therefore, LND is strongly recommended
for stage II or higher thymic malignancies. The lymph
node metastasis rates also differed between the different
WHO histologic subtypes. The node metastasis rates
were 5.8% for thymoma and 25% for thymic carcinoma.
This result echoed that reported by Kondo et al. (1.8%
for thymoma and 26.8% for thymic carcinoma).1 Thus,
LND is more important in thymic carcinoma than in
thymoma. A distinct ﬁnding of our study is that the
lymph node metastasis rate differed between the sub-
types of thymoma. B2 and B3 thymomas showed a
Table 4. Modiﬁed recommendation for lymph node
dissection in thymic malignancies
Lymph nodesa Recommendations
Anterior regional nodes (N1)
Perithymic nodes
Prevascular nodes Routine en bloc dissection
Supradiaphragmatic nodes
Low anterior cervical nodes Sampling in stage I,
dissection in stage II
Para-aortic nodes
Deep regional node (N2)
Right paratracheal nodes Sampling in stage I,
dissection in stage II
Other nodes Sampling in stage II
thymic carcinoma
aAll suspicious nodes should be dissected.
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carcinoma; however, there was no lymph node metas-
tasis in type A, AB, and B1 thymomas. Therefore, LND for
B2 and B3 thymomas should not differ from thymic
carcinoma. Tumor size was also a signiﬁcant factor of
lymph node metastasis, and the optimal cutoff value for
the prediction of node metastasis was 6 cm. It is difﬁcult
to determine the most important predictor of lymph
node metastasis with a small retrospective database
because histologic subtype, tumor size, and stage are
closely related to one another. In particular, a signiﬁcant
correlation between the histologic subtype and the stage
has been well documented.14 As patients are exempted
from preoperative biopsies in cases of resectable tumors,
stage and tumor size are expected to be more important
than histologic subtype in the decision to perform LND
on thymic maliganancies.15 In our study, a preoperative
biopsy was only performed on 16% of patients. Stage
was a more reliable parameter than tumor size. The
current size cutoff value (6 cm) was arbitrary, and the
speciﬁcity (true negative rate) was only 62%. Moreover,
tumor size was not a prognostic factor in the IASLC/
ITMIG staging project.10 On the contrary, the stage
classiﬁcation deﬁnitions are objective parameters based
on data accumulated for several decades, and they were
signiﬁcant prognostic factors in the IASLC/ITMIG staging
project.10 Furthermore, the speciﬁcity was 100% when
the T and M stages were combined. Thus, we suggest
that LND should be selected on the basis of the IASLC/
ITMIG TNM stage classiﬁcation system and that the
suggested indication for LND be stage II (T2N0M0) or
higher.
The extent of the lymph node sampling or dissection
is an issue of practical importance. Suspicious lymph
nodes should be dissected because 69% of the lymph
node metastases were detected in lymph nodes identi-
ﬁed as suspicious on the basis of radiologic studies.
Almost all anterior regional lymph nodes (i.e., peri-
thymic, prevascular, and supradiaphragmatic lymph
nodes) can be easily dissected during total thymectomy
because they are close to the thymus and in the peri-
thymic adipose tissue. Thus, the routine dissection of
these nodes is recommended for all subtypes of thymic
malignancies. In view of the data, in the case of the
remaining anterior regional nodes (the low anterior
cervical and para-aortic nodes) and deep regional lymph
nodes, systematic sampling is recommended at least for
patients with a stage II or higher status. In particular,
right paratracheal LND is strongly recommended in such
patients because the right paratracheal lymph node
group is a crucial station on the lymphatic pathway of
thymic malignancies. In our study, 86% of the N2 node
metastases were detected in the right paratracheal
lymph node group. Frequent right paratracheal lymphnode metastasis was explained in an anatomical study by
Murakami et al.16 The authors reported that the right
paratracheal node chain was consistently well developed
and constituted the primary origin of the right medias-
tinal collecting vessel. Superﬁcial communications be-
tween the lymphatics of the left and right sides in front
of the superior portion of the trachea and above the
aortic arch were frequent. Numerous communications
between the superﬁcial and deep lymphatic pathways in
the right side also existed, whereas the superﬁcial and
deep lymphatic pathways were divided by the aortic
arch and the left pulmonary artery in the left side.16
Lymph node metastasis is an important prognostic
factor in thymic malignancies.17 Kondo et al. reported
that the survival rate was signiﬁcantly worse in thy-
moma and thymic carcinoma with node metastasis.1
Recently, Weksler et al. reported that node metastasis
was a signiﬁcant, independent, and adverse factor (haz-
ard ratio ¼ 1.647 [1.107–2.451], p ¼ 0.019) in survival
in patients with thymoma.18 In our study, the N1/2
groups also showed a signiﬁcantly worse FFR than did
the N0 groups with thymoma and thymic carcinoma.
This study had some limitations. First, no standard
lymph node map or lymph node dissection protocol was
available at the time of the study. Therefore, the extents
and numbers of lymph node dissections were hetero-
geneous. Second, the numbers of patients and events
were small and insufﬁcient for powered statistical ana-
lyses. Because of this limitation, we could not perform
multivariable analyses. The ﬁrst limitation can be over-
come by applying the ITMIG proposals and recommen-
dations prospectively. The second limitation could be
solved with international multi-institutional collaboration.
In conclusion, stage status is the most speciﬁc predictor of
lymph node metastasis and the right paratracheal node
group is a crucial station of lymphatic metastasis in
thymic malignancies. The ITMIG recommendation for LND
114 Hwang et al Journal of Thoracic Oncology Vol. 11 No. 1in thymic malignancy is reasonable but needs to be
modiﬁed in line with the ITMIG/IASLC lymph node map
and the forthcoming (eighth) edition of the TNM stage
classiﬁcation system of thymic malignancies. We suggest a
modiﬁed recommendation for LND in thymic malignancy
(Table 4).
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